Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $1.35, Zacks reports. The business had revenue of $33.45 million during the quarter, compared to analyst estimates of $6.00 million.
Cartesian Therapeutics Stock Performance
RNAC stock traded up $0.50 during trading on Friday, hitting $13.37. The company had a trading volume of 49,521 shares, compared to its average volume of 111,382. The firm has a 50-day moving average price of $21.35 and a 200-day moving average price of $21.34. Cartesian Therapeutics has a 1-year low of $11.66 and a 1-year high of $42.60.
Wall Street Analyst Weigh In
Several equities analysts have commented on RNAC shares. Mizuho initiated coverage on shares of Cartesian Therapeutics in a research note on Friday, May 24th. They issued a “buy” rating and a $40.00 price target for the company. SVB Leerink began coverage on Cartesian Therapeutics in a report on Tuesday, April 23rd. They set an “outperform” rating and a $39.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. Canaccord Genuity Group upped their target price on shares of Cartesian Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. Finally, Oppenheimer downgraded shares of Cartesian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.67.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Further Reading
- Five stocks we like better than Cartesian Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What is a Bond Market Holiday? How to Invest and Trade
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.